Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Hypothyroidism related to immunotherapy in elderly adults: Analysis of a Colombian oncology cohort. Use of steroid-sparing agents (SSAs) for immune-related adverse events (irAEs) in patients (pts) ...

Learn about autoimmune blistering disorders, their types, symptoms, causes, diagnosis, treatment options, complications, and ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition that leads to reddening of the skin and the formation of painful and intensely itchy chronic lesions and blisters ...

Sanofi has unveiled plans to invest “at least” $20bn into the US by 2030, with the commitment including a significant ...

The story of chronic itch and its impact on quality of life is one dermatologists have heard often. Until recently, treatment ...

Clinical review: Bullous pemphigoid Contributed by Dr James Powell, specialist registrar in dermatology, Solihull Hospital, Birmingham. by Dr James Powell Sign in to continue Sign In Email address ...

A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology ...

As May draws to a close, it's time to turn our attention to the FDA's upcoming slate of decisions. From January through May 2025, the U.S. regulatory agency has approved ...

Erythema migrans and erythema multiforme both cause target- or bull’s-eye-shaped lesions. Erythema migrans is due to Lyme disease. Erythema multiforme is an immune-mediated hypersensitivity skin ...

Autoimmune bullous diseases are often associated with significant morbidity and some can even cause mortality, if left untreated. Multiple therapies are now available to treat these blistering ...